Pephexia Therapeutics ApS: Financial statements 2024
CVR: 41319208
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
Pephexia Therapeutics ApS (CVR 41319208) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK -2,085,438 and a net result of DKK -5,320,870 compared with DKK -5,439,731 the year before. Equity in the 2024 report amounted to DKK -15,306,812. The company had 4 employees in the financial year.
- Gross Profit
- DKK -2,085,438
- Profit/Loss
- DKK -5,320,870
- Equity
- DKK -15,306,812
- Total Assets
- DKK 5,893,506
- Employees
- 4
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | -2.1M | -5.3M | -15.3M | 4 |
| 2023 | - | -3.2M | -5.4M | -12.6M | 3 |
| 2022 | - | -5.3M | -6.7M | -7.1M | 3 |
| 2021 | 626K | -4.7M | -4.5M | -2.7M | 0 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
Pephexia Therapeutics ApS has published its annual report for 2023. Gross profit came to DKK -3,212,128, and the net result was DKK -5,439,731.
As of May 22, 2024, Stefan Dietmar Anker has joined the board of directors of Pephexia Therapeutics ApS.
As of May 22, 2024, Yann Albert André Colardelle has left the board of directors of Pephexia Therapeutics ApS.
About Pephexia Therapeutics ApS
Pephexia Therapeutics ApS is a Danish company of the type Anpartsselskab based in Frederiksberg, founded in 2020. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Keld Fogtmann Fosgerau. The board consists of Anders Mørkeberg Hinsby (chair), Andrew Justin Stewart Coats, Keld Fogtmann Fosgerau and Mats Peter Blom. The company is owned by Fogtmann Fosgerau Holding ApS and Andrew Justin Stewart Coats. The company has 5 employees (2026). In 2025, the company reported a gross profit of DKK -179,735 and a net result of DKK -4,440,533 compared with DKK -5,320,870 the year before. Equity in the 2025 report amounted to DKK -19,747,345.